Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286325 · ClinicalTrials.gov registry record · Phase 1
Rituximab in the Treatment of Patients With Bullous Pemphigoid
A Phase 1 study of Bullous Pemphigoid, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00286325 is a Phase 1 study of Bullous Pemphigoid that has completed, run by Duke University. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00286325, a Phase 1 study of Bullous Pemphigoid, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00286325
The ClinicalTrials.gov registry entry for NCT00286325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bullous Pemphigoid appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00286325 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00286325 about?
NCT00286325 is a clinical study titled "Rituximab in the Treatment of Patients With Bullous Pemphigoid". This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
What is the current status of trial NCT00286325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2005-03. Estimated completion is 2010-03.
What conditions does trial NCT00286325 study?
This clinical trial studies the following conditions: Bullous Pemphigoid.
What interventions are being tested in trial NCT00286325?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00286325?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00286325 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bullous Pemphigoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.